The arrival of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 receptor medication suggests to offer significant improvements in weight reduction compared to current therapies. Initial patient tri